Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
EA1151, Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate digital tomosynthesis (3-D) mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Closed for Enrollment
-
A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
Scottsdale/Phoenix, Ariz.
The purpose of this study is to collect user and subject feedback on the design, use and operation of Affirm® Contrast Biopsy.
-
Can Adding Contrast Enhanced Digital Mammography (CEDM) as an Adjunct to Diagnostic Mammography/US Help Decrease Biopsy Rates in Women with Suspicious (BIRADS 4) Breast Lesions?
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the accuracy of diagnosis with contrast enhanced digital mammography when used in addition to standard mammography or ultrasound in patients with suspicious findings.
-
EA1151, Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Rochester, Minn.
The purpose of this study is to evaluate digital tomosynthesis (3-D) mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
-
Screening CEDM in Intermediate and High-Risk Patient Populations
Scottsdale/Phoenix, Ariz.
The primary purpose of this study is to evaluate the incremental invasive cancer yield in patients with a negative mammogram who are intermediate or high-risk for breast cancer and get supplemental screening with Contrast-Enhanced Digital Mammography (CEDM).
-
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Rochester, Minn.,
La Crosse, Wis.,
Jacksonville, Fla.,
Eau Claire, Wis.,
Scottsdale/Phoenix, Ariz.
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to train and validate an assay to detect invasive breast cancer in patients undergoing mammography.
.